(19)
(11) EP 2 904 399 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
13.03.2019 Bulletin 2019/11

(45) Mention of the grant of the patent:
05.12.2018 Bulletin 2018/49

(21) Application number: 13779693.4

(22) Date of filing: 07.10.2013
(51) International Patent Classification (IPC): 
G01N 33/579(2006.01)
B01L 3/00(2006.01)
(86) International application number:
PCT/US2013/063639
(87) International publication number:
WO 2014/058757 (17.04.2014 Gazette 2014/16)

(54)

CENTRIPETAL MICROFLUIDIC PLATFORM FOR LAL-REACTIVE SUBSTANCES TESTING

MIKROFLUIDISCHE ZENTRIPETALE PLATTFORM ZUM TESTEN VON LAL-REAKTIVEN SUBSTANZEN

PLATE-FORME MICROFLUIDIQUE CENTRIPÉTALE PERMETTANT DE TESTER DES SUBSTANCES RÉACTIVES AU TEST LAL


(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 08.10.2012 US 201261710908 P
08.10.2012 US 201261710990 P
08.10.2012 US 201261710898 P
08.10.2012 US 201261710903 P

(43) Date of publication of application:
12.08.2015 Bulletin 2015/33

(73) Proprietor: BL Technologies, Inc.
Minnetonka, MN 55341 (US)

(72) Inventors:
  • MELANSON, Paul Charles
    Boulder Colorado 80301 (US)
  • GODEC, Richard Douglas
    Boulder Colorado 80301 (US)
  • STONESMITH, Matthew Kaddeland
    Boulder Colorado 80301 (US)
  • SMITH, Darren Barry
    Boulder Colorado 80301 (US)
  • SUN, Chao
    Shanghai 201203 (CN)

(74) Representative: Fonquernie, Sophie Benedicte et al
Marks & Clerk France Immeuble Visium 22, avenue Aristide Briand
94117 Arcueil Cedex
94117 Arcueil Cedex (FR)


(56) References cited: : 
EP-A2- 1 983 347
US-A1- 2004 121 450
US-A1- 2009 311 796
US-A1- 2011 143 364
US-A1- 2002 137 218
US-A1- 2005 170 515
US-A1- 2011 124 132
US-A1- 2012 244 607
   
  • Woo Suh Chang ET AL: "Feasibility of on-chip detection of endotoxin by LAL test", Biotechnology and bioprocess engineering, 1 January 2004 (2004-01-01), pages 132-136, XP055095273, Retrieved from the Internet: URL:http://rd.springer.com/content/pdf/10. 1007/BF02932996.pdf [retrieved on 2014-01-08]
  • COOPER JAMES F ET AL: "Automated endotoxin testing program for high-risk-level compounded sterile preparations at an institutional compounding pharmacy.", AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY : AJHP : OFFICIAL JOURNAL OF THE AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS 15 FEB 2010, vol. 67, no. 4, 15 February 2010 (2010-02-15), pages 280-286, XP008166563, ISSN: 1535-2900
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).